Evaxion obtains pre-clinical proof-of-concept for mrna gonorrhea vaccine candidate evx-b2

Copenhagen, denmark, sept. 09, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, announces new pre-clinical data demonstrating the ability of its novel evx-b2 mrna gonorrhea vaccine candidate in eliminating gonorrhea bacteria by triggering a targeted immune response.
EVAX Ratings Summary
EVAX Quant Ranking